Table 2 Clinical trials and preclinical evaluations on Wnt/β-catenin targeted agents in hematological malignancies
From: Targeting the Wnt/β-catenin signaling pathway in cancer
Agents | Mechanism | Phase | Cancer type | Side effects | Identifier |
|---|---|---|---|---|---|
CWP291 | SAM68 inhibitor | Phase 1 | Relapsed or refractory AML and MDS | Nausea, vomiting, diarrhea, and infusion-related reactions | NCT01398462 |
PRI-724 | CBP/β-catenin antagonist | Phase 2 | AML; CML | NR | NCT01606579 |
GNE-781 | CBP antagonist | Preclinical | AML | – | – |
ICG001 | CBP antagonist | Preclinical | AML; ALL; CML; MM | – | – |
WNT974 | PORCN inhibitor | Preclinical | BL | – | |
Wnt-C59 | PORCN inhibitor | Preclinical | cHL | – | |
IWP-2/IWP-4 | PORCN inhibitor | Preclinical | AML; cHL | – | |
XAV939 | Tankyrase inhibitor | Preclinical | AML; T-ALL; CML | – | |
IWR-1 | Tankyrase inhibitor | Preclinical | APL | – | |
Salinomycin | LRP5/6 inhibitor | Preclinical | CLL; MCL | – | |
iCRT14 | β-catenin/TCF | Preclinical | ALL; MCL | – |